Aldali Jehad A, Alotaibi Badi A, Aldali Hamzah J, Alasiri Glowi A, Alaseem Ali, Almuqrin Abdulaziz M, Alshalani Abdulrahman, Alotaibi Fahad T
Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.
Department of Clinical Laboratory Sciences, Collage of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia.
Biomedicines. 2023 Aug 5;11(8):2203. doi: 10.3390/biomedicines11082203.
The coronavirus disease 2019 (COVID-19) vaccines have been developed to help prevent the spread of the virus infections. The COVID-19 vaccines, including Pfizer, Moderna, and AstraZeneca, have undergone rigorous testing and have demonstrated both safety and effectiveness. Extensive evidence supports their effectiveness in preventing severe illness, hospitalization, and mortality associated with COVID-19 infection. The administration of COVID-19 vaccines can directly affect hematological and biochemical parameters, with reported cases showing an association with thrombosis and thrombocytopenia. Therefore, it was hypothesized that COVID-19 vaccines may also influence hematological and biochemical markers in sickle cell patients. This study aimed to investigate the side effects of COVID-19 vaccines on sickle cell patients, providing a comprehensive evaluation of hematological and biochemical parameters. To our knowledge, this is the first study of its kind conducted in Saudi Arabia. The study included the evaluation of Pfizer and Oxford-AstraZeneca vaccines in sickle cell patients, measuring key parameters. Our findings revealed varying impacts of both vaccines on the ALT, AST, and CRP levels. Notably, CRP and ALT exhibited potential as indicators for renal disease, diabetes, and arthritis. However, further investigations are necessary to uncover the underlying mechanisms that drive these observed differences and comprehend their clinical implications for this vulnerable patient population. The unique nature of our study fills a crucial research gap and underscores the need for additional research in this area.
2019冠状病毒病（COVID-19）疫苗已研发出来，以帮助预防病毒感染的传播。包括辉瑞、莫德纳和阿斯利康在内的COVID-19疫苗已经过严格测试，并已证明其安全性和有效性。大量证据支持它们在预防与COVID-19感染相关的严重疾病、住院和死亡方面的有效性。COVID-19疫苗的接种可直接影响血液学和生化参数，报告的病例显示与血栓形成和血小板减少有关。因此，有人推测COVID-19疫苗也可能影响镰状细胞病患者的血液学和生化指标。本研究旨在调查COVID-19疫苗对镰状细胞病患者的副作用，对血液学和生化参数进行全面评估。据我们所知，这是沙特阿拉伯首次进行此类研究。该研究包括对镰状细胞病患者的辉瑞和牛津-阿斯利康疫苗进行评估，测量关键参数。我们的研究结果揭示了两种疫苗对谷丙转氨酶（ALT）、谷草转氨酶（AST）和C反应蛋白（CRP）水平的不同影响。值得注意的是，CRP和ALT有潜力作为肾脏疾病、糖尿病和关节炎的指标。然而，有必要进一步研究以揭示导致这些观察到的差异的潜在机制，并理解它们对这一脆弱患者群体的临床意义。我们研究的独特性质填补了一个关键的研究空白，并强调了在这一领域进行更多研究的必要性。
